Early experience implementing long-acting injectable cabotegravir/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-funded clinic in the US South.

Collins LF, Corbin-Johnson D, Asrat M, et al. Open Forum Infect Dis. 2022;9(9):ofac455.

Weight loss associated with semaglutide treatment among people with HIV.

Haidar L, Crane HM, Nance RM, et al. AIDS. 2023;38(4):531-535.

48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.

Hickey MD, Gistand N, Grochowski J, et al. Clin Infect Dis. 2025;80(4):864-870.

Tirzepatide once weekly for the treatment of obesity.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.

Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities.

Liu Y, Cao W, Sun M, et al. Emerg Microbes Infect. 2020;9(1):194-206.

Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359.

Rana AI, Bao Y, Zheng L, et al. Conference on Retroviruses and Opportunistic Infections; March 3-6, 2024; Denver, CO. Abstract 212.

The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention.

Thavarajah JJ, Hønge BL, Wejse CM. Viruses. 2024;16(6):911.

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.

Venter WDF, Sokhela S, Simmons B, et al. Lancet HIV. 2020;7(10):e666-e676.

Broadly neutralizing antibodies for human immunodeficiency virus treatment: broad in theory, narrow in reality.

Waters L, de Miguel-Buckley R, Poulin S, et al. Clin Infect Dis. 2023;76(6):1136-1141.

Once-weekly semaglutide in adults with overweight or obesity.

Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.